Molnupiravir
Merck boosts revenue outlook on COVID-19 pill Lagevrio demand
Anika Sharma
In a surprising turn of events, Merck’s COVID-19 antiviral pill, Lagevrio, has defied expectations by generating an astounding $640 million ...
Merck’s antiviral pill Lagevrio may have triggered new COVID variants, study suggests
Anika Sharma
As concerns about the coronavirus continue to loom, the spotlight is once again on the most widely used oral antiviral ...
